LENZ – lenz therapeutics, inc. (US:NASDAQ)

News

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics (NASDAQ:LENZ) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Insider Spends US$239k Buying More Shares In LENZ Therapeutics [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com